Abstract

Unlicensed Transdermal Medications in Feline Patients: Three Case Reports

Author(s): Urwin Craig, Jean Linda, Carvalho Maria, Robson-Laws Michael

Issue: Nov/Dec 2022 - Volume 26, Number 6

Page(s): 468-472

Download in electronic PDF format for $75
  • Unlicensed Transdermal Medications in Feline Patients: Three Case Reports Page 1
  • Unlicensed Transdermal Medications in Feline Patients: Three Case Reports Page 2
  • Unlicensed Transdermal Medications in Feline Patients: Three Case Reports Page 3
  • Unlicensed Transdermal Medications in Feline Patients: Three Case Reports Page 4
  • Unlicensed Transdermal Medications in Feline Patients: Three Case Reports Page 5

Abstract

In veterinary clinical practice, conventional pharmacological treatments such as commercial capsules, tablets, or oral liquids may be difficult to administer to feline patients. Noncompliance, which is estimated to account for the majority of treatment failures, may potentially be overcome with alternative, customized treat- ment options such as topically applied, permeation-enhancing (transdermal) unlicensed medications. These medications allow for the percutaneous absorption of drugs into and through the animal’s skin, bypassing the first-pass metabolism, potentially allowing for greater bioavailability, and thus decreasing dosage to achieve therapeutic effects. In these case reports, the efficacy of two unlicensed transdermal medications is demonstrated by the successful treatment of three feline patients, refractory to conventional pharmacotherapy. In case 1, the veterinary physician prescribed gabapentin 10 mg/0.1 mL topical Lipoderm, a permeation-enhancing base, to be applied three times a day inside the cat’s ear, in order to manage the unconscious fits following a road traffic accident. In cases 2 and 3, two cats were prescribed fluoxetine 40-mg/g topical Lipoderm, to be applied once a day, in order to manage the inappropriate behavior (urination and defecation). Following three months of transdermal treatment, the quality of life of the three cats and their owners increased considerably, as demonstrated by the results of the validated, Health Related Quality of Life questionnaires employed before treatment (retrospectively) and after treatment. Permeation-enhancing (transdermal) medications are a promising dosage form in veterinary pharmacotherapy. The benefits and versatility of these alternative, customized treatment options are worth considering in current therapeutics.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2003
Pg. 106-113
Author(s): Davidson Gigi S
Nov/Dec 2022
Pg. 468-472
Sep/Oct 2008
Pg. 392-397
Nov/Dec 2010
Pg. 488-491
Nov/Dec 2006
Pg. 418
Author(s): Fields Shannon W
May/Jun 2010
Pg. 215-217
Author(s): Muller George
Jul/Aug 2016
Pg. 271-274
Author(s): Eichstadt Lauren R
May/Jun 2017
Pg. 205-211
Jan/Feb 2009
Pg. 6-12
Sep/Oct 2009
Pg. 386-389
Sep/Oct 2007
Pg. 390-395
Author(s): Davidson Gigi S
Nov/Dec 2017
Pg. 446-452
Jan/Feb 2011
Pg. 27-31
May/Jun 2011
Pg. 194-199
Author(s): McElhiney Linda F
Nov/Dec 2008
Pg. 498-504
Jan/Feb 2017
Pg. 22-27
Sep/Oct 2014
Pg. 366-369
May/Jun 2011
Pg. 200-203
Author(s): Wynn Tom, Goetsch Daniel
Jan/Feb 2012
Pg. 44-49
Jul/Aug 2001
Pg. 282-283
Author(s): Davidson Gigi S